Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2024 Congress

• Additional analyses of data from AURORA, as well as the full adult data set from BEACON
  
• Updated data from the ongoing Phase 1b study of DISC-0974 in myelofibrosis (MF) patients with anemia, including a larger data set and longer follow-up, to be shared in a poster
  
• Preliminary data on safety and pharmacodynamic activity from initial single-ascending dose (SAD) cohorts of phase 1 study of DISC-3405 in healthy volunteers

WATERTOWN, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced that it will present data from multiple programs in its hematology portfolio at the upcoming European Hematology Association (EHA) 2024 Congress, which will be held in Madrid Spain on June 13-16, 2024.

“We are excited to share four posters at EHA demonstrating the therapeutic potential of our portfolio of three clinical stage drugs,” said John Quisel, J.D., Ph.D., President and Chief Executive Officer of Disc. “We look forward to providing more detailed analyses from the AURORA data, as well as a more robust data set for DISC-0974 in MF anemia, and a first look at DISC-3405 in healthy volunteers.“

Management will host a call to review the presented data on Friday, June 14^th at 8:00 am ET. Please register for the event on the Events and Presentations page of Disc’s website (https://ir.discmedicine.com/).

Details of Presentations and Abstracts

The full abstracts are now available through the EHA conference website. Pursuant to Disc Medicine practice, the abstracts published today contain previously presented data, and new data is planned for presentation at the conference.

Abstract Number: P1575
Title: Topline Results of The AURORA Trial: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial of Bitopertin in Erythropoietic Protoporphyria
Date / Time: Friday, June 14, 6:00 pm CEST / 12 pm ET
Presenter: Amy Dickey, M.D., MSc

Abstract Number: P1569
Title: Results from the BEACON Trial: A Phase 2, Randomized, Open-Label Trial of Bitopertin in Erythropoietic Protoporphyria
Date / Time: Friday, June 14, 6:00 pm CEST / 12 pm ET
Presenter: Gayle Ross, M.D.

Abstract Number: P1059
Title: A Phase 1b Trial of DISC-0974, An Anti-Hemojuvelin Antibody, in Patients with Myelofibrosis and Anemia